Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our modelEdwards Life ( EW) pushed the Health Services industry higher today making it today's featured health services winner. The industry as a whole closed the day down 0.4%. By the end of trading, Edwards Life rose $1.51 (2.3%) to $66.46 on average volume. Throughout the day, 2,026,122 shares of Edwards Life exchanged hands as compared to its average daily volume of 1,462,600 shares. The stock ranged in a price between $64.25-$67.29 after having opened the day at $64.65 as compared to the previous trading day's close of $64.95. Other companies within the Health Services industry that increased today were: Uroplasty ( UPI), up 18.8%, MGC Diagnostics ( MGCD), up 12.9%, Kips Bay Medical ( KIPS), up 8.6% and Nanosphere ( NSPH), up 8.0%.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Life has a market cap of $7.3 billion and is part of the health care sector. The company has a P/E ratio of 20.3, above the S&P 500 P/E ratio of 17.7. Shares are down 28.0% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate Edwards Life a buy, 1 analyst rates it a sell, and 9 rate it a hold. TheStreet Ratings rates Edwards Life as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.